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The European School of Genetic Medicine organised
the 26th Course in Medical Genetics and the 2nd Course
in Next Generation Sequencing, between the 12th and
20th May 2013. Both courses were webcast live from
the Bologna University Residential Centre, Bertinoro,
Italy. Participants in Malta attended these courses at
the University’s Medical School.
The course in Medical Genetics covered various as-
pects of this rapidly developing field of Medicine. The
different methodologies used in human genome analysis,
an introduction to Next Generation Sequencing (NGS),
approaches to clinical and molecular genetics, complex
genetic disorders, therapy and gene regulation, were
covered.
The second course provided a comprehensive insight
into NGS technologies, from the basics to the new world
of disease gene identification by hand-held devices. It
also covered insights into bioinformatics challenges,
sample preservation and trans-omic studies, and new
frontiers including the investigation of single cells and
of the non-coding genome.
Medical Genetics or Genetic Medicine as it is in-
creasingly being referred to nowadays, is a constantly
changing clinical specialty. In the past 15 years there
has been a massive increase in referrals of conditions
regarded as common complex disorders such as breast
and bowel cancer, and some cardiac diseases. An
increase in the range of medical genetic services has
benefited patients with genetic disorders and their
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families. “Careful clinical observation is at the heart
of medical genetic practice” (Donnai xxxx). “The new
technologies enabling targeted capture and massively
parallel sequencing of individual genomes/exomes,
have resulted in major discoveries on small clinically
well characterised patients” (Donnai xxxx). Through
the identification of novel genes, new developmental
pathways have been discovered; many disorders with
overlapping clinical features shown to be due to muta-
tions in functionally related genes, might be responsive
to treatment by similar molecules (Donnai xxxx).
Prof van Duijn delivered an interesting presenta-
tion entitled ‘Complex Disease Genetics: GWAS and
beyond’. Whole genome association studies using
Affymetrix R©/ Illumina R©arrays, have revealed in-
creased number of variants involved in complex disease.
Sometimes it is difficult to predict the genetic risk
for conditions such as dyslipidaemia and Alzheimer’s
disease. Genome tests are currently limited with
respect to their predictive ability (van Duijn xxxx).
“In the near future, personal genome tests would very
likely be based on whole genome sequencing, but will
these technological advances increase the utility of
personal genome testing? The utility of testing depends
on the predictive ability of the test, the likelihood of
actionable test results, and the options available for the
reduction of risks” (van Duijn xxxx). The identification
of new variants in monogenic diseases could present a
challenge due to the number of rare disease variants.
The complexity of disease aetiology and disease her-
itability will affect the prediction of genetic risk for
complex diseases. New omic technologies will aid in the
discovery of biomarkers which could be used to improve
predictions (van Duijn xxxx).
Next generation sequencing is a technological rev-
olution in genomics which will have a major impact
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on the entire field of medicine. “All genomic vari-
ation that can be linked to disease is detectable in
a single experiment!” (Veltman xxxx). In the near
future it will soon be possible to sequence an entire
genome at an affordable price which will lead to
personalised medicine. Important characteristics of
NGS platforms include: accuracy, ease of mapping /
assembly sequence, sequence throughput / coverage,
application, robustness, ease of interpretation and
costs (Veltman xxxx). “The unbiased sequencing of
the exome has become an integral part of the toolkit
for genetics researchers” (Gilissen xxxx). Exome
sequencing of trios (mother, father, child) are being
offered to families of individuals with unknown disor-
ders. Patients with specific disorders such as retinal
dystrophy, cataract and epilepsy are being offered
targeted testing using large panels of genes (Donnai
xxxx). Preliminary results of diagnostic applications
of NGS show that there is a much wider phenotypic
spectrum associated with mutations in many genes
than was previously thought. There have been concerns
about the ethical aspects of NGS but as experience
increases most centres are finding ways of addressing
these in conjunction with patient groups (Donnai xxxx).
Handheld diagnostics on nanowires was one of the
fascinating presentations during the NGS course. A
novel, cheap, portable, handheld DNA sequencing de-
vice, is being developed by QuantumMDx for infectious
disease applications at point of care testing, as an
alternative to slow and relatively expensive capillary
electrophoresis DNA sequencing (O’Halloran xxxx).
The presentation entitled ’Sample Preservation and
Trans-omic Studies to Accelarate Scientific Research’
delved into the use, requirements and benefits of
biobanking. “Fast development of sequencing technol-
ogy with decreasing cost has substantially promoted
large cohort study, population health screening, and
epidemiological prevention study on a genomic level”
(Cheng xxxx). The 100 million US dollar China
National Genebank (Shenzhen), operated by the
Beijing Genomics Institute (BGI), aims at combining
large bio-specimen collection and transcriptomic data
production to accelerate scientific discovery and trans-
lation to clinical use (Cheng xxxx). “The Genebank
has accumulated genetic variation information of more
than 2000 monogenetic diseases by collecting suspected
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pedigree samples countrywide and worldwide” (Cheng
xxxx). It also established databases of global human
genetic variation, cancer genetic variation and human
inhabited microbial composition which are essential for
understanding human disease and in the development
of personalised medicine.
The faculty members for both webcast courses were
internationally renowned experts in the field of Medical
Genetics. The cutting edge lectures delivered during
both courses, provided a golden opportunity for post-
graduate research students studying at the University
of Malta, to widen and update their knowledge on the
latest developments in Medical Genetics, and also on
the technologies used in analysing genetic data.
The courses were organised by Dr Isabella Borg, Direc-
tor of the European School of Genetic Medicine, Malta
Remote Training Centre, based at the University of
Malta Medical School, with the assistance of Ms Joanna
Vella from the Malta BioBank. Funding was provided
by the Malta BioBank, University of Malta, as part of
the training initiative.
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